120 related articles for article (PubMed ID: 19495690)
41. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading.
Subramaniam JR; Lyons WE; Liu J; Bartnikas TB; Rothstein J; Price DL; Cleveland DW; Gitlin JD; Wong PC
Nat Neurosci; 2002 Apr; 5(4):301-7. PubMed ID: 11889469
[TBL] [Abstract][Full Text] [Related]
42. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS.
Hall ED; Andrus PK; Oostveen JA; Fleck TJ; Gurney ME
J Neurosci Res; 1998 Jul; 53(1):66-77. PubMed ID: 9670993
[TBL] [Abstract][Full Text] [Related]
43. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy.
Acsadi G; Anguelov RA; Yang H; Toth G; Thomas R; Jani A; Wang Y; Ianakova E; Mohammad S; Lewis RA; Shy ME
Hum Gene Ther; 2002 Jun; 13(9):1047-59. PubMed ID: 12067438
[TBL] [Abstract][Full Text] [Related]
44. Treatment of a Mouse Model of ALS by In Vivo Base Editing.
Lim CKW; Gapinske M; Brooks AK; Woods WS; Powell JE; Zeballos C MA; Winter J; Perez-Pinera P; Gaj T
Mol Ther; 2020 Apr; 28(4):1177-1189. PubMed ID: 31991108
[TBL] [Abstract][Full Text] [Related]
45. Ascending neuropathology in the CNS of a mutant SOD1 mouse model of amyotrophic lateral sclerosis.
Leichsenring A; Linnartz B; Zhu XR; Lübbert H; Stichel CC
Brain Res; 2006 Jun; 1096(1):180-95. PubMed ID: 16737688
[TBL] [Abstract][Full Text] [Related]
46. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.
Nizzardo M; Simone C; Falcone M; Riboldi G; Rizzo F; Magri F; Bresolin N; Comi GP; Corti S
Cell Mol Life Sci; 2012 May; 69(10):1641-50. PubMed ID: 22094924
[TBL] [Abstract][Full Text] [Related]
47. GAB(A) receptors present higher affinity and modified subunit composition in spinal motor neurons from a genetic model of amyotrophic lateral sclerosis.
Carunchio I; Mollinari C; Pieri M; Merlo D; Zona C
Eur J Neurosci; 2008 Oct; 28(7):1275-85. PubMed ID: 18973555
[TBL] [Abstract][Full Text] [Related]
48. Glutamate release induced by activation of glycine and GABA transporters in spinal cord is enhanced in a mouse model of amyotrophic lateral sclerosis.
Raiteri L; Zappettini S; Stigliani S; Paluzzi S; Raiteri M; Bonanno G
Neurotoxicology; 2005 Oct; 26(5):883-92. PubMed ID: 15885796
[TBL] [Abstract][Full Text] [Related]
49. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis.
Kira Y; Nishikawa M; Ochi A; Sato E; Inoue M
Brain Res; 2006 Jan; 1070(1):206-14. PubMed ID: 16412993
[TBL] [Abstract][Full Text] [Related]
50. High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation.
Wang J; Xu G; Borchelt DR
Neurobiol Dis; 2002 Mar; 9(2):139-48. PubMed ID: 11895367
[TBL] [Abstract][Full Text] [Related]
51. In vivo application of an RNAi strategy for the selective suppression of a mutant allele.
Kubodera T; Yamada H; Anzai M; Ohira S; Yokota S; Hirai Y; Mochizuki H; Shimada T; Mitani T; Mizusawa H; Yokota T
Hum Gene Ther; 2011 Jan; 22(1):27-34. PubMed ID: 20649474
[TBL] [Abstract][Full Text] [Related]
52. [Gene therapy of ALS with RNA interference].
Yokota T
Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
[TBL] [Abstract][Full Text] [Related]
53. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.
Lepore AC; Haenggeli C; Gasmi M; Bishop KM; Bartus RT; Maragakis NJ; Rothstein JD
Brain Res; 2007 Dec; 1185():256-65. PubMed ID: 17963733
[TBL] [Abstract][Full Text] [Related]
54. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2.
Azzouz M; Hottinger A; Paterna JC; Zurn AD; Aebischer P; Büeler H
Hum Mol Genet; 2000 Mar; 9(5):803-11. PubMed ID: 10749988
[TBL] [Abstract][Full Text] [Related]
55. RNA interference and amyotrophic lateral sclerosis.
Rizvanov AA; Gulluoglu S; Yalvaç ME; Palotás A; Islamov RR
Curr Drug Metab; 2011 Sep; 12(7):679-83. PubMed ID: 21740381
[TBL] [Abstract][Full Text] [Related]
56. Current developments in gene therapy for amyotrophic lateral sclerosis.
Scarrott JM; Herranz-Martín S; Alrafiah AR; Shaw PJ; Azzouz M
Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
[TBL] [Abstract][Full Text] [Related]
57. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit.
Henriques A; Pitzer C; Dittgen T; Klugmann M; Dupuis L; Schneider A
Mol Ther; 2011 Feb; 19(2):284-92. PubMed ID: 21139572
[TBL] [Abstract][Full Text] [Related]
58. Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord.
Peluffo H; Foster E; Ahmed SG; Lago N; Hutson TH; Moon L; Yip P; Wanisch K; Caraballo-Miralles V; Olmos G; Lladó J; McMahon SB; Yáñez-Muñoz RJ
Gene Ther; 2013 Jun; 20(6):645-57. PubMed ID: 23076378
[TBL] [Abstract][Full Text] [Related]
59. Gene Therapy for ALS-A Perspective.
Cappella M; Ciotti C; Cohen-Tannoudji M; Biferi MG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500113
[TBL] [Abstract][Full Text] [Related]
60. RNAi silencing in mouse models of neurodegenerative diseases.
Farah MH
Curr Drug Deliv; 2007 Apr; 4(2):161-7. PubMed ID: 17456035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
